GeneCast Bio Announces Tumor Early Screening and Companion Diagnostics Satellite Symposia at CSCO 2021
On September 25, 2021, the 24th National Clinical Oncology Conference and the 2021 CSCO Annual Academic Meeting kicked off in a hybrid format, combining online and offline participation. Genetron Health, a leading enterprise in China’s gene testing industry for whole-course cancer management, will host two special sessions on early cancer screening and companion diagnostics on September 27 (18:00–19:30) and September 28 (12:30–14:00), respectively. Both sessions will be live-streamed nationwide via an online platform. Stay tuned for these insightful programs!
Hardcore | From Craftsmanship to Original Aspiration, from Quest to Truth
Special Session on Early Cancer Screening
September 27, 18:00–19:30
● Single-dimensional liquid biopsy indicators fail to meet the performance requirements for early screening products; what value will multi-dimensional testing bring to early cancer detection?
● What new breakthroughs can the results of the prospective study on early screening for liver cancer (PreCar-S) bring to early detection?
● What new insights and benefits will the application of HIFI technology to lung cancer bring to precise early screening for the disease?
● How much potential will pyramid-style stratified screening, which improves early diagnosis rates, and cfDNA whole-genome sequencing-based multi-dimensional early screening technology for liver cancer demonstrate in clinical practice?
Precision | Seeing the Big Picture from Subtle Clues, Driving Integration
Companion Diagnostics in Oncology Special Session
September 28, 12:30–14:00
● Dynamic prospective studies have established the benchmark for MRD testing. How can further breakthroughs be achieved to reshape the future treatment landscape for lung cancer patients?
● How can technological innovation be leveraged to overcome challenges, particularly those associated with liquid biopsy, and truly achieve integrated detection at both the DNA and RNA levels?
● Can multi-dimensional, innovative detection technologies achieve liquid biopsy-based prediction of PD-L1 expression, opening a new window for immunotherapy?
Herui Gene is a genetic testing company dedicated to comprehensive, whole-course cancer management. Guided by its mission to “enable early diagnosis and treatment for all cancers and ensure precision therapy for every patient,” the company has established a complete product and service system for genetic testing tailored to high-risk populations and cancer patients. This system encompasses a range of offerings, including cancer genetic susceptibility analysis, early screening, targeted and immunotherapy companion diagnostics, treatment response monitoring, and prognostic assessment. In the field of early cancer screening and diagnosis, Herui Gene has initiated clinical research projects for the early detection of liver cancer, lung cancer, and other malignancies with high prevalence and risk in China. The company has completed a strategic layout featuring three centers—laboratory, supercomputing, and R&D—across two locations (Fuzhou and Beijing). Committed to providing more precise cancer genetic testing services for clinical oncology care and personal health management, Herui Gene’s collaborative and service network covers over 700 renowned hospitals across China, having delivered valuable genetic testing services to hundreds of thousands of cancer patients.